A spoonful of sugar makes the melanoma go: The role of heparan sulfate proteoglycans in melanoma metastasis

Pigment Cell and Melanoma Research

Volumn 24, Issue 6, 2011, Pages 1133-1147

  O'Connell, M P ^a   Weeraratna, A T ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Heparan sulfate proteoglycans; Melanoma; Wnt; Wnt5A

Indexed keywords

CELL PROTEIN; FIBROBLAST GROWTH FACTOR; GLYCOSYLTRANSFERASE; GLYPICAN; GLYPICAN 1; GLYPICAN 3; HEPARANASE; HEPARIN LYASE; PROTEIN EPAC1; PROTEOHEPARAN SULFATE; SULFATASE; SYNDECAN; SYNDECAN 1; SYNDECAN 2; SYNDECAN 3; SYNDECAN 4; UNCLASSIFIED DRUG; WNT PROTEIN;

CELL SURFACE; HUMAN; MELANOMA; METASTASIS; NEOPLASM; NONHUMAN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; STRUCTURE ANALYSIS;

ANIMALS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; SKIN NEOPLASMS;

EID: 81955167397     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2011.00918.x     Document Type: Review

References (133)

1. Aikawa, J., and Esko, J.D. (1999). Molecular cloning and expression of a third member of the heparan sulfate/heparin GlcNAc N-deacetylase/N-sulfotransferase family. J. Biol. Chem. 274, 2690-2695.
2. Aikawa, T., Whipple, C.A., Lopez, M.E., Gunn, J., Young, A., Lander, A.D., and Korc, M. (2008). Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J. Clin. Invest. 118, 89-99.
3. Andres, J.L., Stanley, K., Cheifetz, S., and Massague, J. (1989). Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta. J. Cell Biol. 109(Pt 1), 3137-3145.
4. Andres, J.L., DeFalcis, D., Noda, M., and Massague, J. (1992). Binding of two growth factor families to separate domains of the proteoglycan betaglycan. J. Biol. Chem. 267, 5927-5930.
5. Aono, S., Keino, H., Ono, T., Yasuda, Y., Tokita, Y., Matsui, F., Taniguchi, M., Sonta, S., and Oohira, A. (2000). Genomic organization and expression pattern of mouse neuroglycan C in the cerebellar development. J. Biol. Chem. 275, 337-342.
6. Arvatz, G., Shafat, I., Levy-Adam, F., Ilan, N., and Vlodavsky, I. (2011). The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev. 30, 253-268.
7. Baasanjav, S., Al-Gazali, L., Hashiguchi, T. et al. (2011). Faulty initiation of proteoglycan synthesis causes cardiac and joint defects. Am. J. Hum. Genet. 89, 15-27.
8. Bai, S., Thomas, C., and Ahsan, F. (2007). Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin. J. Pharm. Sci. 96, 2090-2106.
9. Baljinnyam, E., Iwatsubo, K., Kurotani, R., Wang, X., Ulucan, C., Iwatsubo, M., Lagunoff, D., and Ishikawa, Y. (2009). Epac increases melanoma cell migration by a heparan sulfate-related mechanism. Am. J. Physiol. Cell Physiol. 297, C802-C813.
10. Belting, M., Borsig, L., Fuster, M.M., Brown, J.R., Persson, L., Fransson, L.A., and Esko, J.D. (2002). Tumor attenuation by combined heparan sulfate and polyamine depletion. Proc. Natl. Acad. Sci. USA 99, 371-376.
11. Bernfield, M., Kokenyesi, R., Kato, M., Hinkes, M.T., Spring, J., Gallo, R.L., and Lose, E.J. (1992). Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu. Rev. Cell Biol. 8, 365-393.
12. Bernfield, M., Gotte, M., Park, P.W., Reizes, O., Fitzgerald, M.L., Lincecum, J., and Zako, M. (1999). Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68, 729-777.
13. Birch, M.A., and Skerry, T.M. (1999). Differential regulation of syndecan expression by osteosarcoma cell lines in response to cytokines but not osteotropic hormones. Bone 24, 571-578.
14. Bishop, J.R., Schuksz, M., and Esko, J.D. (2007). Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446, 1030-1037.
15. Bret, C., Moreaux, J., Schved, J.F., Hose, D., and Klein, B. (2011). SULFs in human neoplasia: implication as progression and prognosis factors. J. Transl. Med. 9, 72.
16. Brule, S., Friand, V., Sutton, A., Baleux, F., Gattegno, L., and Charnaux, N. (2009). Glycosaminoglycans and syndecan-4 are involved in SDF-1/CXCL12-mediated invasion of human epitheloid carcinoma HeLa cells. Biochim. Biophys. Acta 1790, 1643-1650.
17. Burbach, B.J., Ji, Y., and Rapraeger, A.C. (2004). Syndecan-1 ectodomain regulates matrix-dependent signaling in human breast carcinoma cells. Exp. Cell Res. 300, 234-247.
18. Camilli, T.C., Xu, M., O'Connell, M.P., Chien, B., Frank, B.P., Subaran, S., Indig, F.E., Morin, P.J., Hewitt, S.M., and Weeraratna, A.T. (2011). Loss of Klotho during melanoma progression leads to increased filamin cleavage, increased Wnt5A expression, and enhanced melanoma cell motility. Pigment Cell Melanoma Res. 24, 175-186.
19. Campoli, M., Ferrone, S., and Wang, X. (2010). Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv. Cancer Res. 109, 73-121.
20. Capurro, M.I., Xu, P., Shi, W., Li, F., Jia, A., and Filmus, J. (2008). Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev. Cell 14, 700-711.
21. Carey, D.J. (1997). Syndecans: multifunctional cell-surface co-receptors. Biochem. J. 327(Pt 1), 1-16.
22. Carvallo, L., Munoz, R., Bustos, F., Escobedo, N., Carrasco, H., Olivares, G., and Larrain, J. (2010). Non-canonical Wnt signaling induces ubiquitination and degradation of Syndecan 4. J. Biol. Chem. 285, 29546-29555.
23. Cha, S.K., Ortega, B., Kurosu, H., Rosenblatt, K.P., Kuro, O.M., and Huang, C.L. (2008). Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc. Natl. Acad. Sci. USA 105, 9805-9810.
24. Chalkiadaki, G., Nikitovic, D., Berdiaki, A., Sifaki, M., Krasagakis, K., Katonis, P., Karamanos, N.K., and Tzanakakis, G.N. (2009). Fibroblast growth factor-2 modulates melanoma adhesion and migration through a syndecan-4-dependent mechanism. Int. J. Biochem. Cell Biol. 41, 1323-1331.
25. Chang, Q., Hoefs, S., van der Kemp, A.W., Topala, C.N., Bindels, R.J., and Hoenderop, J.G. (2005). The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 310, 490-493.
26. Charni, F., Friand, V., Haddad, O., Hlawaty, H., Martin, L., Vassy, R., Oudar, O., Gattegno, L., Charnaux, N., and Sutton, A. (2009). Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells. Biochim. Biophys. Acta 1790, 1314-1326.
27. Chen, R.L., and Lander, A.D. (2001). Mechanisms underlying preferential assembly of heparan sulfate on glypican-1. J. Biol. Chem. 276, 7507-7517.
28. Chen, K., Liu, M.L., Schaffer, L., Li, M., Boden, G., Wu, X., and Williams, K.J. (2010). Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins. Hepatology 52, 1957-1967.
29. Chien, A.J., Moore, E.C., Lonsdorf, A.S., Kulikauskas, R.M., Rothberg, B.G., Berger, A.J., Major, M.B., Hwang, S.T., Rimm, D.L., and Moon, R.T. (2009). Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc. Natl. Acad. Sci. USA 106, 1193-1198.
30. Choi, S., Clements, D.J., Pophristic, V., Ivanov, I., Vemparala, S., Bennett, J.S., Klein, M.L., Winkler, J.D., and DeGrado, W.F. (2005). The design and evaluation of heparin-binding foldamers. Angew. Chem. Int. Ed. Engl. 44, 6685-6689.
31. David, G., Lories, V., Decock, B., Marynen, P., Cassiman, J.J., and Van den Berghe, H. (1990). Molecular cloning of a phosphatidylinositol-anchored membrane heparan sulfate proteoglycan from human lung fibroblasts. J. Cell Biol. 111(Pt 2), 3165-3176.
32. De Cat, B., and David, G. (2001). Developmental roles of the glypicans. Semin. Cell Dev. Biol. 12, 117-125.
33. Dieudonne, F.X., Marion, A., Hay, E., Marie, P.J., and Modrowski, D. (2010). High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells. Cancer Res. 70, 5399-5408.
34. Dissanayake, S.K., and Weeraratna, A.T. (2008). Detecting PKC phosphorylation as part of the Wnt/calcium pathway in cutaneous melanoma. Methods Mol. Biol. 468, 157-172.
35. Dissanayake, S.K., Wade, M., Johnson, C.E. et al. (2007). The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J. Biol. Chem. 282, 17259-17271.
36. Echtermeyer, F., Bertrand, J., Dreier, R. et al. (2009). Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat. Med. 15, 1072-1076.
37. Engbring, J.A., Hoffman, M.P., Karmand, A.J., and Kleinman, H.K. (2002). The B16F10 cell receptor for a metastasis-promoting site on laminin-1 is a heparan sulfate/chondroitin sulfate-containing proteoglycan. Cancer Res. 62, 3549-3554.
38. Esko, J.D., and Selleck, S.B. (2002). Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 71, 435-471.
39. Filmus, J., Capurro, M., and Rast, J. (2008). Glypicans. Genome Biol. 9, 224.
40. Fransson, L.A. (2003). Glypicans. Int. J. Biochem. Cell Biol. 35, 125-129.
41. Fromm, J.R., Hileman, R.E., Weiler, J.M., and Linhardt, R.J. (1997). Interaction of fibroblast growth factor-1 and related peptides with heparan sulfate and its oligosaccharides. Arch. Biochem. Biophys. 346, 252-262.
42. Fuster, M.M., Wang, L., Castagnola, J. et al. (2007). Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. J. Cell Biol. 177, 539-549.
43. Gutsche, C.D. (1989). Calixarenes (Cambridge: Royal Society of Chemistry).
44. Hameetman, L., David, G., Yavas, A., White, S.J., Taminiau, A.H., Cleton-Jansen, A.M., Hogendoorn, P.C., and Bovee, J.V. (2007). Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas. J. Pathol. 211, 399-409.
45. Hasengaowa, Kodama, J., Kusumoto, T., Shinyo, Y., Seki, N., and Hiramatsu, Y. (2005). Prognostic significance of syndecan-1 expression in human endometrial cancer. Ann. Oncol. 16, 1109-1115.
46. Hayashi, K., Hayashi, M., Jalkanen, M., Firestone, J.H., Trelstad, R.L., and Bernfield, M. (1987). Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study. J. Histochem. Cytochem. 35, 1079-1088.
47. Herndon, M.E., Stipp, C.S., and Lander, A.D. (1999). Interactions of neural glycosaminoglycans and proteoglycans with protein ligands: assessment of selectivity, heterogeneity and the participation of core proteins in binding. Glycobiology 9, 143-155.
48. Hershkovitz, O., Jivov, S., Bloushtain, N., Zilka, A., Landau, G., Bar-Ilan, A., Lichtenstein, R.G., Campbell, K.S., van Kuppevelt, T.H., and Porgador, A. (2007). Characterization of the recognition of tumor cells by the natural cytotoxicity receptor, NKp44. Biochemistry 46, 7426-7436.
49. Ho, M., and Kim, H. (2011). Glypican-3: a new target for cancer immunotherapy. Eur. J. Cancer 47, 333-338.
50. Hoek, K.S., Eichhoff, O.M., Schlegel, N.C., Dobbeling, U., Kobert, N., Schaerer, L., Hemmi, S., and Dummer, R. (2008). In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 68, 650-656.
51. Honsova, E., Lodererova, A., Frankova, S., Oliverius, M., and Trunecka, P. (2011). Glypican-3 immunostaining significantly improves histological diagnosis of hepatocellular carcinoma. Cas. Lek. Cesk. 150, 37-40.
52. Hovingh, P., and Linker, A. (1970). The enzymatic degradation of heparin and heparitin sulfate. 3. Purification of a heparitinase and a heparinase from flavobacteria. J. Biol. Chem. 245, 6170-6175.
53. Hulett, M.D., Freeman, C., Hamdorf, B.J., Baker, R.T., Harris, M.J., and Parish, C.R. (1999). Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat. Med. 5, 803-809.
54. Ikuta, Y., Nakatsura, T., Kageshita, T., Fukushima, S., Ito, S., Wakamatsu, K., Baba, H., and Nishimura, Y. (2005). Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin. Cancer Res. 11, 8079-8088.
55. Iozzo, R.V. (2005). Basement membrane proteoglycans: from cellar to ceiling. Nat. Rev. Mol. Cell Biol. 6, 646-656.
56. Kainulainen, V., Wang, H., Schick, C., and Bernfield, M. (1998). Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids. J. Biol. Chem. 273, 11563-11569.
57. Kandil, D., Leiman, G., Allegretta, M., and Evans, M. (2009). Glypican-3 protein expression in primary and metastatic melanoma: a combined immunohistochemistry and immunocytochemistry study. Cancer 117, 271-278.
58. Karumanchi, S.A., Jha, V., Ramchandran, R. et al. (2001). Cell surface glypicans are low-affinity endostatin receptors. Mol. Cell 7, 811-822.
59. Kato, M., Wang, H., Kainulainen, V., Fitzgerald, M.L., Ledbetter, S., Ornitz, D.M., and Bernfield, M. (1998). Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat. Med. 4, 691-697.
60. Kirsch, T., Koyama, E., Liu, M., Golub, E.E., and Pacifici, M. (2002). Syndecan-3 is a selective regulator of chondrocyte proliferation. J. Biol. Chem. 277, 42171-42177.
61. Kisilevsky, R., Szarek, W.A., Ancsin, J., Vohra, R., Li, Z., and Marone, S. (2004). Novel glycosaminoglycan precursors as antiamyloid agents: Part IV. J. Mol. Neurosci. 24, 167-172.
62. Kleeff, J., Ishiwata, T., Kumbasar, A., Friess, H., Buchler, M.W., Lander, A.D., and Korc, M. (1998). The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J. Clin. Invest. 102, 1662-1673.
63. Konduri, S.D., Tasiou, A., Chandrasekar, N., Nicolson, G.L., and Rao, J.S. (2000). Role of tissue factor pathway inhibitor-2 (TFPI-2). in amelanotic melanoma (C-32) invasion. Clin. Exp. Metastasis 18, 303-308.
64. Kosher, R.A. (1998). Syndecan-3 in limb skeletal development. Microsc. Res. Tech. 43, 123-130.
65. Kurosu, H., Ogawa, Y., Miyoshi, M. et al. (2006). Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 281, 6120-6123.
66. Lai, J.P., Sandhu, D.S., Yu, C. et al. (2008). Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 47, 1211-1222.
67. Lai, J.P., Sandhu, D.S., Yu, C. et al. (2010). Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. Liver Int. 30, 1522-1528.
68. Latysheva, N., Muratov, G., Rajesh, S., Padgett, M., Hotchin, N.A., Overduin, M., and Berditchevski, F. (2006). Syntenin-1 is a new component of tetraspanin-enriched microdomains: mechanisms and consequences of the interaction of syntenin-1 with CD63. Mol. Cell. Biol. 26, 7707-7718.
69. Lee, J.H., Park, H., Chung, H. et al. (2009). Syndecan-2 regulates the migratory potential of melanoma cells. J. Biol. Chem. 284, 27167-27175.
70. Lee, H., Kim, Y., Choi, Y., Choi, S., Hong, E., and Oh, E.S. (2011). Syndecan-2 cytoplasmic domain regulates colon cancer cell migration via interaction with syntenin-1. Biochem. Biophys. Res. Commun. 409, 148-153.
71. Lendorf, M.E., Manon-Jensen, T., Kronqvist, P., Multhaupt, H.A., and Couchman, J.R. (2011). Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. J. Histochem. Cytochem. 59, 615-629.
72. Li, J., Hagner-McWhirter, A., Kjellen, L., Palgi, J., Jalkanen, M., and Lindahl, U. (1997). Biosynthesis of heparin/heparan sulfate. cDNA cloning and expression of D-glucuronyl C5-epimerase from bovine lung. J. Biol. Chem. 272, 28158-28163.
73. Li, F., Shi, W., Capurro, M., and Filmus, J. (2011). Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. J. Cell Biol. 192, 691-704.
74. Lin, Y.L., Lei, Y.T., Hong, C.J., and Hsueh, Y.P. (2007). Syndecan-2 induces filopodia and dendritic spine formation via the neurofibromin-PKA-Ena/VASP pathway. J. Cell Biol. 177, 829-841.
75. Lindahl, U., and Li, J.P. (2009). Interactions between heparan sulfate and proteins-design and functional implications. Int. Rev. Cell Mol. Biol. 276, 105-159.
76. Liu, D., Shriver, Z., Venkataraman, G., El Shabrawi, Y., and Sasisekharan, R. (2002). Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 99, 568-573.
77. Lugemwa, F.N., Sarkar, A.K., and Esko, J.D. (1996). Unusual beta-D-xylosides that prime glycosaminoglycans in animal cells. J. Biol. Chem. 271, 19159-19165.
78. Luo, W., Wang, X., Kageshita, T., Wakasugi, S., Karpf, A.R., and Ferrone, S. (2006). Regulation of high molecular weight-melanoma associated antigen (HMW-MAA). gene expression by promoter DNA methylation in human melanoma cells. Oncogene 25, 2873-2884.
79. Mani, K., Havsmark, B., Persson, S. et al. (1998). Heparan/chondroitin/dermatan sulfate primer 2-(6-hydroxynaphthyl)-O-beta-D-xylopyranoside preferentially inhibits growth of transformed cells. Cancer Res. 58, 1099-1104.
80. Martin, N.B., Masson, P., Sepulchre, C., Theveniaux, J., Millet, J., and Bellamy, F. (1996). Pharmacologic and biochemical profiles of new venous antithrombotic beta-D-xyloside derivatives: potential antiathero/thrombotic drugs. Semin. Thromb. Hemost. 22, 247-254.
81. Matsui, Y., Ikesue, M., Danzaki, K., Morimoto, J., Sato, M., Tanaka, S., Kojima, T., Tsutsui, H., and Uede, T. (2011). Syndecan-4 prevents cardiac rupture and dysfunction after myocardial infarction. Circ. Res. 108, 1328-1339.
82. Mecca, T., Consoli, G.M., Geraci, C., La Spina, R., and Cunsolo, F. (2006). Polycationic calix[8]arenes able to recognize and neutralize heparin. Org. Biomol. Chem. 4, 3763-3768.
83. Munesue, S., Yoshitomi, Y., Kusano, Y. et al. (2007). A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J. Biol. Chem. 282, 28164-28174.
84. Murry, B.P., Greiter-Wilke, A., Paulsen, D.P., Hiatt, K.M., Beltrami, C.A., and Marchetti, D. (2005). Selective heparanase localization in malignant melanoma. Int. J. Oncol. 26, 345-352.
85. Nakatsura, T., and Nishimura, Y. (2005). Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs 19, 71-77.
86. Nikitovic, D., Assouti, M., Sifaki, M., Katonis, P., Krasagakis, K., Karamanos, N.K., and Tzanakakis, G.N. (2008). Chondroitin sulfate and heparan sulfate-containing proteoglycans are both partners and targets of basic fibroblast growth factor-mediated proliferation in human metastatic melanoma cell lines. Int. J. Biochem. Cell Biol. 40, 72-83.
87. Norgard-Sumnicht, K., and Varki, A. (1995). Endothelial heparan sulfate proteoglycans that bind to L-selectin have glucosamine residues with unsubstituted amino groups. J. Biol. Chem. 270, 12012-12024.
88. O'Connell, M.P., Fiori, J.L., Baugher, K.M. et al. (2009a). Wnt5A activates the calpain-mediated cleavage of filamin A. J. Invest. Dermatol. 129, 1782-1789.
89. O'Connell, M.P., Fiori, J.L., Kershner, E.K., Frank, B.P., Indig, F.E., Taub, D.D., Hoek, K.S., and Weeraratna, A.T. (2009b). Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells. J. Biol. Chem. 284, 28704-28712.
90. O'Connell, M.P., Fiori, J.L., Xu, M. et al. (2010). The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 29, 34-44.
91. Orellana, A., Hirschberg, C.B., Wei, Z., Swiedler, S.J., and Ishihara, M. (1994). Molecular cloning and expression of a glycosaminoglycan N-acetylglucosaminyl N-deacetylase/N-sulfotransferase from a heparin-producing cell line. J. Biol. Chem. 269, 2270-2276.
92. Pearson, A.G., Kiefel, M.J., Ferro, V., and von Itzstein, M. (2011). Synthesis of simple heparanase substrates. Org. Biomol. Chem. 9, 4614-4625.
93. Penc, S.F., Pomahac, B., Eriksson, E., Detmar, M., and Gallo, R.L. (1999). Dermatan sulfate activates nuclear factor-kappab and induces endothelial and circulating intercellular adhesion molecule-1. J. Clin. Invest. 103, 1329-1335.
94. Pluschke, G., Vanek, M., Evans, A., Dittmar, T., Schmid, P., Itin, P., Filardo, E.J., and Reisfeld, R.A. (1996). Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc. Natl. Acad. Sci. USA 93, 9710-9715.
95. Rapraeger, A.C. (2001). Molecular interactions of syndecans during development. Semin. Cell Dev. Biol. 12, 107-116.
96. Rapraeger, A., Jalkanen, M., and Bernfield, M. (1986). Cell surface proteoglycan associates with the cytoskeleton at the basolateral cell surface of mouse mammary epithelial cells. J. Cell Biol. 103(Pt 2), 2683-2696.
97. Reiland, J., Sanderson, R.D., Waguespack, M., Barker, S.A., Long, R., Carson, D.D., and Marchetti, D. (2004). Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J. Biol. Chem. 279, 8047-8055.
98. Reiland, J., Kempf, D., Roy, M., Denkins, Y., and Marchetti, D. (2006). FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Neoplasia 8, 596-606.
99. Ridgway, L.D., Wetzel, M.D., and Marchetti, D. (2010). Modulation of GEF-H1 induced signaling by heparanase in brain metastatic melanoma cells. J. Cell. Biochem. 111, 1299-1309.
100. Roy, M., and Marchetti, D. (2009). Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis. J. Cell. Biochem. 106, 200-209.
101. Schmidt, P., Kopecky, C., Hombach, A., Zigrino, P., Mauch, C., and Abken, H. (2011). Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc. Natl. Acad. Sci. USA 108, 2474-2479.
102. Schuksz, M., Fuster, M.M., Brown, J.R., Crawford, B.E., Ditto, D.P., Lawrence, R., Glass, C.A., Wang, L., Tor, Y., and Esko, J.D. (2008). Surfen, a small molecule antagonist of heparan sulfate. Proc. Natl. Acad. Sci. USA 105, 13075-13080.
103. Seykora, J.T., Jih, D., Elenitsas, R., Horng, W.H., and Elder, D.E. (2003). Gene expression profiling of melanocytic lesions. Am. J. Dermatopathol. 25, 6-11.
104. Simons, K., and Toomre, D. (2000). Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1, 31-39.
105. Sloand, E.M., Kessler, C.M., McIntosh, C.L., and Klein, H.G. (1989). Methylene blue for neutralization of heparin. Thromb. Res. 54, 677-686.
106. Song, H.H., Shi, W., Xiang, Y.Y., and Filmus, J. (2005). The loss of glypican-3 induces alterations in Wnt signaling. J. Biol. Chem. 280, 2116-2125.
107. Strunz, C.M., Matsuda, M., Salemi, V.M., Nogueira, A., Mansur, A.P., Cestari, I.N., and Marquezini, M.V. (2011). Changes in cardiac heparan sulfate proteoglycan expression and streptozotocin-induced diastolic dysfunction in rats. Cardiovasc. Diabetol. 10, 35.
108. Su, G., Blaine, S.A., Qiao, D., and Friedl, A. (2007). Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J. Biol. Chem. 282, 14906-14915.
109. Subramanian, S.V., Fitzgerald, M.L., and Bernfield, M. (1997). Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J. Biol. Chem. 272, 14713-14720.
110. Sun, X., Mosher, D.F., and Rapraeger, A. (1989). Heparan sulfate-mediated binding of epithelial cell surface proteoglycan to thrombospondin. J. Biol. Chem. 264, 2885-2889.
111. Suzuki, M., Sugimoto, K., Tanaka, J. et al. (2010). Up-regulation of glypican-3 in human hepatocellular carcinoma. Anticancer Res. 30, 5055-5061.
112. Talhaoui, I., Bui, C., Oriol, R., Mulliert, G., Gulberti, S., Netter, P., Coughtrie, M.W., Ouzzine, M., and Fournel-Gigleux, S. (2010). Identification of key functional residues in the active site of human {beta}1, 4-galactosyltransferase 7: a major enzyme in the glycosaminoglycan synthesis pathway. J. Biol. Chem. 285, 37342-37358.
113. Tohyama, O., Imura, A., Iwano, A., Freund, J.N., Henrissat, B., Fujimori, T., and Nabeshima, Y. (2004). Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides. J. Biol. Chem. 279, 9777-9784.
114. Tumova, S., Woods, A., and Couchman, J.R. (2000). Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int. J. Biochem. Cell Biol. 32, 269-288.
115. Vlodavsky, I., Friedmann, Y., Elkin, M. et al. (1999). Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 5, 793-802.
116. Wang, J., and Rabenstein, D.L. (2006). Interaction of heparin with two synthetic peptides that neutralize the anticoagulant activity of heparin. Biochemistry 45, 15740-15747.
117. Wang, J.B., Zhang, Y.J., Guan, J., Zhou, L., Sheng, Y., Zhang, Y., and Si, Y.F. (2011a). Enhanced syndecan-1 expression on neutrophils in patients with type 2 diabetes mellitus. Acta Diabetol. doi:.
118. Wang, Z., Telci, D., and Griffin, M. (2011b). Importance of syndecan-4 and syndecan-2 in osteoblast cell adhesion and survival mediated by a tissue transglutaminase-fibronectin complex. Exp. Cell Res. 317, 367-381.
119. Weeraratna, A.T., Jiang, Y., Hostetter, G., Rosenblatt, K., Duray, P., Bittner, M., and Trent, J.M. (2002). Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1, 279-288.
120. Weng, T., and Liu, L. (2010). The role of pleiotrophin and beta-catenin in fetal lung development. Respir. Res. 11, 80.
121. Whiteford, J.R., Xian, X., Chaussade, C., Vanhaesebroeck, B., Nourshargh, S., and Couchman, J.R. (2011). Syndecan-2 is a novel ligand for the protein tyrosine phosphatase receptor CD148. Mol. Biol. Cell, 22, 3609-3624.
122. Woods, A., and Couchman, J.R. (1994). Syndecan 4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component. Mol. Biol. Cell 5, 183-192.
123. Wright, A.T., Zhong, Z., and Anslyn, E.V. (2005). A functional assay for heparin in serum using a designed synthetic receptor. Angew. Chem. Int. Ed. Engl. 44, 5679-5682.
124. Wu, H., Barusevicius, A., Babb, J., Klein-Szanto, A., Godwin, A., Elenitsas, R., Gelfand, J.M., Lessin, S., and Seykora, J.T. (2005). Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. J. Cutan. Pathol. 32, 125-130.
125. Wu, Y., Belenkaya, T.Y., and Lin, X. (2010). Dual roles of Drosophila glypican Dally-like in Wingless/Wnt signaling and distribution. Methods Enzymol. 480, 33-50.
126. Yan, D., and Lin, X. (2009). Shaping morphogen gradients by proteoglycans. Cold Spring Harb. Perspect. Biol. 1, a002493.
127. Yang, Y., MacLeod, V., Dai, Y. et al. (2007). The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 110, 2041-2048.
128. Yang, J., Price, M.A., Li, G.Y., Bar-Eli, M., Salgia, R., Jagedeeswaran, R., Carlson, J.H., Ferrone, S., Turley, E.A., and McCarthy, J.B. (2009). Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res. 69, 7538-7547.
129. Zak, B.M., Crawford, B.E., and Esko, J.D. (2002). Hereditary multiple exostoses and heparan sulfate polymerization. Biochim. Biophys. Acta 1573, 346-355.
130. Zhang, J., Riverst, G., Zhu, Y. et al. (2001). Identification of inhibitors of heparin-growth factor interactions from combinatorial libraries of four-component condensation reactions. Bioorg. Med. Chem. 9, 825-836.
131. Zhou, H., Roy, S., Cochran, E. et al. (2011). M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS ONE 6, e21106.
132. Zimmermann, P., and David, G. (1999). The syndecans, tuners of transmembrane signaling. FASEB J. 13(Suppl), S91-S100.
133. Zou, Z.Q., Ding, Y.P., Long, B., Yuh, J.G., Xu, A.L., Lang, Z.W., Zou, S.Y., Liu, Y.D., Ding, K., and Li, Y.Y. (2010). Gpc-3 is a notable diagnostic, prognostic and a latent targeted therapy marker in hepatocellular carcinoma. Hepatogastroenterology 57, 1285-1290.